✨ Free AI Report
Cadrenal Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cadrenal Therapeutics, Inc.
Company Research

Cadrenal Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Cadrenal Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). High-risk, high-reward clinical-stage biotech with differentiated mechanisms targeting orphan thrombotic diseases, near-term catalysts, and strong insider support. With a market capitalization of $19.41 million, Cadrenal is a small-cap biotech entity with no revenue and negative earnings per share of -8.76. An End-of-Phase 2 meeting for CAD-1005 is scheduled this.

What is Cadrenal Therapeutics, Inc.'s industry? Cadrenal Therapeutics, Inc. (cadrenal.com) operates in Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics. AskCyborg classifies Cadrenal Therapeutics, Inc. under Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics in its company registry.

Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company targets orphan indications with narrow therapeutic windows w...

6/ 10Solid

Cyborg Score thesis

High-risk, high-reward clinical-stage biotech with differentiated mechanisms targeting orphan thrombotic diseases, near-term...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cadrenal Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cadrenal Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Cadrenal Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cadrenal Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cadrenal Therapeutics, Inc. Overview

Pro stress-test →

Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company targets orphan indications with narrow therapeutic windows where existing anticoagulants fail, representing a significant unmet medical need in rare cardiovascular and immune disorders.

Strategic Profile

Pro stress-test →

Cadrenal develops novel and differentiated biopharmaceutical products to bridge essential gaps in currently available anticoagulation therapeutics. The company's 12-LOX inhibitor portfolio represents a differentiated platform approach across a range of thrombotic and inflammatory conditions, with both acute and chronic potential applications.

Competitive Landscape

Pro stress-test →

Existing treatments such as warfarin and DOACs (Eliquis, Xarelto) often do not meet the needs of patients with orphan cardiovascular conditions, creating an addressable market gap. Cadrenal's tecarfarin and 12-LOX inhibitors target specific high-risk patient populations abandoned by conventional anticoagulants, differentiating it from large-cap pharma competitors focused on broader markets.

Industry Context

Cadrenal Therapeutics, Inc. operates in Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics.

Key facts

Headquarters: Ponte Vedra, US · Revenue: $0 · Market cap: $12.81M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cadrenal Therapeutics, Inc..

  • Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia demonstrated a reduction in thrombotic events on a background of standard anticoagulants.
  • The broader pipeline includes tecarfarin (Phase 3-ready vitamin K antagonist) and frunexian (parenteral Factor XIa inhibitor for acute hospital settings).
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026End-of-Phase 2 meeting scheduled for CAD-1005 in heparin-induced thrombocytopenia
  • March 2026Expanded pipeline with acquisition of selective 12-LOX inhibitors including oral candidates
  • +1 moreTrack every material event for Cadrenal Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Cadrenal Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

WarfarinTraditional oral anticoagulant with narrow therapeutic window→Eliquis (apixaban)DOAC with limited efficacy in kidney disease patients→Xarelto (rivaroxaban)DOAC with limited efficacy in kidney disease patients→

Compare Cadrenal Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cadrenal Therapeutics, Inc. operates in Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics research →
NEW · MCP server

Ask your AI assistant about Cadrenal Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cadrenal Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Cadrenal Therapeutics, Inc. do this quarter?”
“Is Cadrenal Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cadrenal Therapeutics, Inc. do?+
Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company targets orphan indications with narrow therapeutic windows w...
What is Cadrenal Therapeutics, Inc.'s Cyborg Score?+
Cadrenal Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cadrenal Therapeutics, Inc.'s main competitors?+
Named competitors include Warfarin, Eliquis (apixaban), Xarelto (rivaroxaban). The full competitive landscape is in the AskCyborg report.
How can I get the full Cadrenal Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cadrenal Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cadrenal Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.